ClinicalTrials.gg

Program

GP MDI

Also written as “GP MDI 28.8 μg”, “GP MDI 14.4 μg” and “GP MDI 7.2 μg”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive, led by AstraZeneca.

Furthest: phase 3, since May 13, 20133 company-led studies, 1 open or runningNext primary completion: May 23, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca31 open or runningphase 3since May 13, 2013May 13, 2013May 23, 2029phase 2 · NCT07525375

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2013First study: phase 3 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT01854645 · 2,103 enrolled · United States, Australia, New Zealand
  2. Nov 20, 2017Phase 3 study in AsthmaNCT03358147 · 1,077 enrolled · United States
  3. Apr 7, 2026Phase 2 study in AsthmaNCT07525375 · 69 planned · United States, Argentina, Czechia and more

Ahead

  1. May 23, 2029Primary completion: phase 2 study in AsthmaNCT07525375

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07525375Asthma · United States, Argentina, Czechia and more2RecruitingMay 23, 202969
NCT03358147Asthma · United States3CompletedSep 12, 20191,077
NCT01854645Pulmonary Disease, Chronic Obstructive · United States, Australia, New Zealand3CompletedFeb 20152,103

How it is read

Names in the registry

  • “GP MDI”, 2 entries
  • “GP MDI 28.8 μg”, 1 entry
  • “GP MDI 14.4 μg”, 1 entry
  • “GP MDI 7.2 μg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.